← All trials
NCT03950843
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 23, 2019
- Primary completion
- Sep 30, 2021
- Completion date
- Dec 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 162
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chong Kun Dang PharmaceuticalLead sponsor
- Chonbuk National UniversityOverall official - principal investigator
- Gachon UniversityOverall official - principal investigator
- Catholic University of KoreaOverall official - principal investigator
- Yonsei UniversityOverall official - principal investigator
- Kyung Hee UniversityOverall official - principal investigator
- Chungnam National UniversityOverall official - principal investigator
- Inha UniversityOverall official - principal investigator
- University of UlsanOverall official - principal investigator
- Sungkyunkwan UniversityOverall official - principal investigator
- Ajou UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Inje UniversityOverall official - principal investigator
- Sejong General HospitalOverall official - principal investigator
- Dong-A UniversityOverall official - principal investigator
- Hanyang UniversityOverall official - principal investigator
- Chonnam National UniversityOverall official - principal investigator
- Wonkwang UniversityOverall official - principal investigator
- Keimyung UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.